Director/PDMR Shareholding

RNS Number : 7369P
GlaxoSmithKline PLC
19 February 2021
 

GlaxoSmithKline plc   (the ' Company ')

 

Conditional Share Awards and Shares withheld or sold to meet tax liabilities

This notification sets out details of the vesting of awards made in 2018 under the GlaxoSmithKline Share Value Plan and the subsequent sale of Ordinary Shares to meet tax liabilities arising on the vesting. The awards, which were conditional on continued employment with the GlaxoSmithKline group, vested on 15 February 2021.

 

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms D Conrad

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

The vesting of Ordinary Shares awarded in 2018 under the Company's Share Value Plan.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£0.00

10,050

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

e)

Date of the transaction

2021-02-15

f)

Place of the transaction

 

N/A

   

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms D Conrad

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

Following the vesting of Ordinary Shares awarded in 2018 under the Company's Share Value Plan, Ms Conrad received a cash amount of £127,452.09 (less applicable tax withholding) which is equal to the market value of the number of Ordinary Shares which would otherwise have been transferred to her.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£12.6818

10,050

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

e)

Date of the transaction

2021-02-17

f)

Place of the transaction

 

N/A

  

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms S Jackson

b)

Position/status

SVP, Global Communications & CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

The vesting of Ordinary Shares awarded in 2018 under the Company's Share Value Plan.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£0.00

11,060

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

e)

Date of the transaction

2021-02-15

f)

Place of the transaction

 

N/A

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms S Jackson

b)

Position/status

SVP, Global Communications & CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2018 under the Company's Share Value Plan. 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£12.6818

5,199

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

e)

Date of the transaction

2021-02-15

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Jackson

b)

Position/status

PCA of Ms S Jackson (SVP, Global Communications & CEO Office)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

The vesting of Ordinary Shares awarded in 2018 under the Company's Share Value Plan.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£0.00

6,330

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

e)

Date of the transaction

2021-02-15

f)

Place of the transaction

 

N/A

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Jackson

b)

Position/status

PCA of Ms S Jackson (SVP, Global Communications & CEO Office)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2018 under the Company's Share Value Plan. 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£12.6818

2,976

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

e)

Date of the transaction

2021-02-15

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms D Waterhouse

b)

Position/status

CEO of ViiV Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

The vesting of Ordinary Shares awarded in 2018 under the Company's Share Value Plan.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£0.00

15,160

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

e)

Date of the transaction

2021-02-15

f)

Place of the transaction

 

N/A

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms D Waterhouse

b)

Position/status

CEO of ViiV Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2018 under the Company's Share Value Plan. 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£12.6818

7,126

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

e)

Date of the transaction

2021-02-15

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms V Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

The vesting of Ordinary Shares awarded in 2018 under the Company's Share Value Plan.

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£0.00

11,060

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

e)

Date of the transaction

2021-02-15

f)

Place of the transaction

 

N/A

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms V Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

b)

Nature of the transaction

The sale of Ordinary Shares to meet tax liabilities on the vesting of awards granted in 2018 under the Company's Share Value Plan. 

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

 

 

£12.6818

5,199

 

 

 

 

 

d)

Aggregated information

 

N/A (single transaction)

 

Aggregated volume Price

 

e)

Date of the transaction

2021-02-15

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBKLFFFLLXBBF

Companies

GSK (GSK)
UK 100

Latest directors dealings